Core Viewpoint - The research highlights the critical role of GPX4 in preventing ferroptosis, a form of cell death linked to neurodegenerative diseases, emphasizing the importance of its membrane localization alongside its enzymatic activity [2][10]. Group 1: Ferroptosis and GPX4 - Ferroptosis is a newly identified iron-dependent form of cell death characterized by the accumulation of lipid peroxides, distinct from other forms of programmed cell death [1]. - GPX4 is recognized as a key regulator of ferroptosis, primarily known for its enzymatic activity in detoxifying lipid peroxides [5]. - The study identifies a specific mutation in the GPX4 gene (GPX4 R152H) that disrupts its membrane localization, impairing its protective function against ferroptosis despite retaining enzymatic activity [5][8]. Group 2: Implications for Neurodegenerative Diseases - The research provides molecular evidence linking ferroptosis to neurodegenerative diseases, particularly through the study of a rare condition known as Sedaghatian type spondyloepiphyseal dysplasia (SSMD) [2][4]. - In mouse models, the absence of GPX4 or expression of the GPX4 R152H mutation leads to neuronal death and neuroinflammation, mirroring the pathological processes observed in SSMD [7]. - The findings suggest that ferroptosis may also play a significant role in more common neurodegenerative diseases, such as Alzheimer's disease, as similar protein expression patterns were observed in both conditions [7][10]. Group 3: Research Findings and Future Directions - The study establishes that the membrane localization of GPX4 is as crucial as its enzymatic activity for neuroprotection against ferroptosis [10]. - It underscores the potential of targeting ferroptosis as a therapeutic strategy for neurodegenerative diseases, providing a strong theoretical basis for future drug development [10]. - The research chain from genetic mutation to animal models and human cell models reinforces the conclusion that ferroptosis is a key driver of neurodegenerative changes [10].

Core Viewpoint - Ferroptosis is emerging as a promising anti-tumor therapy driven by the oxidation of polyunsaturated fatty acids in cell membranes, leading to lipid peroxidation and cell death, while also releasing damage-associated molecular patterns (DAMPs) that enhance T cell activation [1][4]. Summary by Sections Ferroptosis Mechanism and Challenges - Ferroptosis induces cell death through increased intracellular iron, reduced glutathione synthesis, and elevated reactive oxygen species (ROS) levels. However, the upregulation of PD-L1 in tumor cells can inhibit cytotoxic T cell recognition, leading to immune suppression [1][5]. Research Development - A team from Shenyang Pharmaceutical University and Shenzhen University developed a fluorinated prodrug-engineered nano-remodeler that combines a PD-L1 inhibitor (JQ1) and a ferroptosis inducer (sorafenib) to enhance oxygen supply in hypoxic tumors, significantly improving the efficacy of ferroptosis and anti-tumor immunogenicity [2][6]. Nano-remodeler Characteristics - The engineered nano-remodeler (FJSO NA) has high oxygen solubility and releases oxygen in low-pressure environments, alleviating hypoxia in solid tumors, downregulating PD-L1 expression, and enhancing ferroptosis induction and anti-tumor immune responses [6][8]. Efficacy and Safety - The study demonstrated that the nano-remodeler effectively inhibited tumor growth in various models without significant toxicity, indicating a promising direction for enhancing ferroptosis-based immunotherapy by addressing the hypoxic tumor microenvironment [8].

Core Viewpoint - Ferroptosis is a newly discovered iron-dependent form of programmed cell death that plays a significant role in cancer and other diseases, with potential implications for immunotherapy and radiotherapy [1][2]. Group 1: Ferroptosis Mechanism and Importance - Ferroptosis is characterized by the accumulation of peroxidized lipids and is distinct from other forms of cell death [1]. - Key defense mechanisms against ferroptosis include GPX4, which inhibits ferroptosis by catalyzing peroxidized lipids, and FSP1, which promotes cancer cell resistance to ferroptosis through the antioxidant form of coenzyme Q10 [1]. Group 2: Research Findings on Lung Cancer - A study published on November 5, 2025, demonstrated that targeting FSP1 triggers ferroptosis in lung cancer, indicating that lung cancer is highly sensitive to ferroptosis [4][6]. - The research showed that the knockout of the FSP1 gene in tumors led to increased lipid peroxidation and significant tumor suppression, highlighting the protective role of FSP1 in vivo [6][7]. - FSP1 expression is prognostic for disease progression and survival in lung adenocarcinoma patients, suggesting its potential as a therapeutic target [7][9]. Group 3: FSP1 in Melanoma - Another study indicated that FSP1 targeting in the lymph node environment could effectively inhibit the progression of metastatic melanoma [10][16]. - The research found that metastatic melanoma cells showed decreased expression of GCLC and reduced levels of GSH in the hypoxic lymphatic microenvironment, leading to increased reliance on FSP1 [13][16]. - Selective FSP1 inhibitors demonstrated significant efficacy in suppressing melanoma growth in lymph nodes, emphasizing the specific dependency of melanoma cells on FSP1 in that microenvironment [13][16].

Core Viewpoint - Systemic treatment is the best option for patients with unresectable or advanced hepatocellular carcinoma (HCC), but its efficacy is limited by drug resistance [2][3]. Group 1: Research Findings - Ferroptosis is a unique form of regulated cell death that plays a crucial role in the systemic treatment of HCC [3]. - A study published in Nature Cancer reveals that SCRN1 confers resistance to ferroptosis in HCC by stabilizing GPX4 through STK38-mediated phosphorylation, providing potential therapeutic targets and strategies for HCC treatment [4][8]. - The research team found that high expression of SCRN1 is closely related to ferroptosis resistance and poor prognosis in HCC [7]. Group 2: Mechanism of Action - SCRN1 enhances the interaction between STK38 and GPX4, promoting the phosphorylation of GPX4 at the S45 site, which impairs HSC70's recognition of GPX4 and reduces its degradation via chaperone-mediated autophagy, thereby alleviating lipid peroxidation and ferroptosis [7][8].

Core Viewpoint - The article discusses the emerging focus on metabolic cell death as a new frontier in cancer therapy, highlighting the significance of ferroptosis, cuproptosis, and disulfidptosis as potential therapeutic targets against cancer cells that evade traditional cell death pathways [3][4][5]. Group 1: Metabolic Cell Death Mechanisms - Metabolic cell death is characterized by the collapse of metabolic homeostasis, leading to irreversible cell death due to nutrient deprivation or the accumulation of harmful metabolites [3]. - Ferroptosis, discovered in 2012, is an iron-dependent cell death mechanism that results from uncontrolled lipid peroxidation, leading to membrane damage [8]. - Cuproptosis, identified in 2022, is a copper-dependent cell death mechanism where excess copper ions induce protein toxicity by binding to fatty acylated proteins in mitochondria [14]. - Disulfidptosis, proposed in 2023, occurs when cystine accumulation leads to the collapse of the actin cytoskeleton under conditions of glucose deprivation or NADPH depletion [19]. Group 2: Cancer Treatment Implications - Targeting metabolic cell death pathways presents a unique opportunity to exploit cancer cells' vulnerabilities, particularly through the mechanisms of ferroptosis, cuproptosis, and disulfidptosis [5][26]. - The interplay between these pathways suggests that combined interventions could enhance therapeutic efficacy and overcome drug resistance in cancer treatment [24][26]. - Establishing verifiable biomarker systems is crucial for advancing clinical applications and achieving precise patient stratification and treatment [26].

Core Insights - Ferroptosis is a regulated form of cell death characterized by iron-dependent lipid peroxidation, gaining attention for its potential in cancer therapy [2][6] - Despite extensive research on the biological mechanisms of ferroptosis, its anti-tumor effects are significantly limited due to challenges in the precise delivery of ferroptosis inducers to tumor tissues [2][4] Group 1: Biological Mechanisms and Challenges - Cancer remains a major global health challenge and a leading cause of death, with traditional therapies like chemotherapy and radiotherapy facing inherent limitations such as drug resistance and reduced efficacy in hypoxic tumor microenvironments [6] - Ferroptosis, first reported in 2012, offers a promising opportunity to overcome clinical bottlenecks faced by traditional cancer therapies, with its therapeutic effects validated in various cancer types including pancreatic ductal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, and triple-negative breast cancer [6][7] - The need to enhance the delivery efficiency of ferroptosis inducers to tumor tissues is a critical theme, as several inducers have shown effectiveness in preclinical models but failed to improve patient survival in clinical trials [7][9] Group 2: Nanotechnology and Delivery Systems - Recent advancements in nanotechnology provide new perspectives for the innovation of tumor ferroptosis, particularly through the development of nanodrug delivery systems (NDDS) that can regulate multiple molecular pathways and enhance tumor-specific delivery [4][8] - Multifunctional nanomaterials can serve as nanocarriers for the synergistic delivery of various therapeutic agents, overcoming ferroptosis resistance in cancer cells and effectively targeting multiple molecular pathways [8][9] - NDDS can be designed to respond to tumor-specific stimuli, allowing for spatiotemporal controlled release of ferroptosis inducers, thereby minimizing off-target damage and enhancing therapeutic efficacy [8][9] Group 3: Future Directions - The review establishes a connection between the biology of ferroptosis and nanomaterial science, elucidating how functional nanoplatforms can enhance ferroptosis by modulating dysfunctional organelles and improving the delivery efficiency of inducers [9][27] - The current limitations of ferroptosis in clinical applications and the future development directions based on nanotechnology are summarized, indicating a significant potential for improving clinical outcomes and patient quality of life through enhanced ferroptosis cancer therapies [9][27]

Core Insights - Lung cancer is a leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases, and lung adenocarcinoma (LUAD) being the most common subtype. The five-year survival rate for lung adenocarcinoma patients is below 26% [2] - The study published in Cell Discovery reveals that ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing the degradation of ACSL4 in lung adenocarcinoma, identifying a key regulatory factor in the resistance to ferroptosis and proposing a new strategy for cancer treatment based on ferroptosis [3][8] Group 1: Ferroptosis and Cancer Treatment - Ferroptosis is a regulated form of cell death characterized by the accumulation of reactive oxygen species (ROS), lipid peroxides, and increased levels of divalent iron (Fe2+), showing significant effectiveness in overcoming resistance to traditional cancer therapies [5] - The study indicates that ferroptosis significantly increases lactate accumulation and subsequent protein lactylation, which contributes to the resistance of lung adenocarcinoma cells to ferroptosis [6] Group 2: Key Findings of the Research - SUMO2-K11 lactylation is identified as a critical factor determining the resistance to ferroptosis in lung adenocarcinoma, as it weakens the interaction between SUMO2 and ACSL4, promoting ACSL4 degradation and disrupting lipid metabolism [6][8] - AARS1 is recognized as the lactylation transferase for SUMO2-K11la, while HDAC1 acts as the de-lactylase. The research team developed a cell-penetrating peptide that specifically inhibits SUMO2-K11la, enhancing ferroptosis and increasing the sensitivity of lung adenocarcinoma to the chemotherapy drug cisplatin [6][8]

Core Insights - Cell ferroptosis has been confirmed to be related to the development of various liver diseases [1] - A new study from Japan indicates that two volatile molecules produced during ferroptosis can be detected in the breath of patients [1] Group 1: Research Findings - Ferroptosis is a specific type of programmed cell death characterized by abnormal accumulation of iron ions and lipid peroxidation [1] - The main pathological process of ferroptosis involves irreversible damage to cell membrane structures due to lipid peroxidation, leading to loss of cell function [1] - Current detection methods for ferroptosis primarily rely on invasive tissue biopsies, which impose significant burdens on patients [1] Group 2: Methodology and Implications - Researchers from Kyoto University and other institutions utilized a newly developed oxidative volatile organic compound analysis technique to study volatile molecules released during ferroptosis [1] - The study identified two "iron-smelling molecules" that increase in concentration as ferroptosis progresses [1] - These molecules were found to be elevated in both the liver and breath of liver disease model mice, as well as in the breath of liver disease patients [1] Group 3: Future Applications - Based on the research findings, alternative methods to liver biopsy could be developed for health diagnostics and monitoring the progression of liver diseases [2] - The research results have been published in the journal "Redox Biology" [2]

Core Viewpoint - Immunotherapy, particularly immune checkpoint blockade (ICB), presents transformative potential for treating various malignancies, but challenges such as acquired resistance and immune-related adverse events (irAEs) persist, necessitating a dual approach to address both thromboembolic risks and treatment resistance [2][5]. Group 1: Research Findings - A study published in Cell Reports Medicine indicates that the antiplatelet drug Vorapaxar enhances mitochondria-associated ferroptosis, thereby improving cancer immunotherapy outcomes by targeting the FOXO1/HMOX1 axis [3][6]. - Vorapaxar, approved by the FDA in 2014, reversibly inhibits the PAR-1 receptor on platelets, blocking thrombin-mediated platelet activation, which is crucial for antithrombotic therapy [6]. - The study confirms that Vorapaxar binds to FOXO1, inhibiting its phosphorylation and promoting its nuclear translocation, leading to increased expression of heme oxygenase-1 (HMOX1) and subsequent mitochondrial iron overload and ferroptosis [6]. Group 2: Clinical Implications - Vorapaxar has been shown to enhance immune therapy-induced tumor ferroptosis and antitumor immunity in various melanoma mouse models, suggesting its potential as a powerful adjunct in immunotherapy [6][8]. - High co-expression of FOXO1/HMOX1 is associated with improved responses to immunotherapy and prolonged progression-free survival, indicating a promising biomarker for treatment efficacy [6][8]. - Overall, Vorapaxar is positioned as a dual-benefit solution for cancer patients requiring both thrombolytic and immunotherapeutic interventions, addressing the dual challenges of thromboembolism and treatment resistance [8].

Core Viewpoint - The study reveals that HEBP2-mediated glutamine competition between tumor cells and macrophages dictates the efficacy of immunotherapy in triple-negative breast cancer (TNBC), identifying GSTP1 as a new therapeutic target to enhance treatment outcomes [3][4]. Group 1: Research Findings - The research team developed a single-cell RNA sequencing (scRNA-seq) immune therapy cohort (N=27) and a spatial transcriptomics cohort (N=88) to elucidate the metabolic interactions related to TNBC treatment efficacy [5]. - High expression of HEBP2 in tumor cells, characterized by active glutathione metabolism, and CCL3+ macrophages, characterized by oxidative metabolism, indicate effective immunotherapy, showing a negative correlation in quantity and spatial distribution [5]. - HEBP2 disrupts the cytoplasmic phase separation of the transcription factor FOXA1, promoting its nuclear translocation, which upregulates GSTP1 expression and glutamine consumption in tumor cells [5][6]. Group 2: Implications for Treatment - The metabolic shift induced by HEBP2 leads to ferroptosis in CCL3+ macrophages, impairing anti-tumor immunity [5]. - The use of GSTP1 inhibitors (Ezatiostat) can block this pathway, preventing excessive glutamine consumption by tumor cells, thereby protecting macrophages and restoring anti-tumor immunity, making TNBC more sensitive to cancer immunotherapy (anti-PD-1 monoclonal antibodies) [5][7]. - The findings establish a metabolic checkpoint regulated by the HEBP2/GSTP1 signaling axis, pioneering the assessment of immune metabolic weaknesses at the single-cell level [6][7].